LivaNova (LIVN) Stock Price
LivaNova Price
LivaNova (LIVN) Stock | ISIN GB00BYMT0J19 | WKN A14156. The current LivaNova stock price is 78.38 USD (2026). Revenue is 1.5 B USD. Net income is 230.1 M USD. The P/E ratio is 18.59. Market capitalization is 4.28 B USD. LivaNova operates in the Health sector.
Over the last 19 years LivaNova grew revenue by 13% annually, reaching 1.25 B USD. Earnings per share have grown at 1.1% per year over the last 16 years. For LivaNova, the net margin of 5% is up versus -37.3% a few years ago.
LivaNova stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of LivaNova over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how LivaNova stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing LivaNova's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | LivaNova Price |
|---|
LivaNova Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
LivaNova Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|
| 1.15 | 1.25 | 1.41 | 1.5 | 1.6 | 1.72 | 1.77 | 1.95 |
| 12.93 | 8.67 | 12.29 | 6.61 | 6.6 | 7.32 | 3.15 | 10 |
| 66.87 | 69.43 | 61.83 | 58 | 54.41 | 50.7 | 49.15 | 44.68 |
| 771 | 870 | 870 | 870 | 870 | 870 | 870 | 870 |
| 17 | 63 | 214 | 230 | 247 | 283 | 341 | 395 |
| -119.77 | 270.59 | 239.68 | 7.48 | 7.39 | 14.57 | 20.49 | 15.84 |
| 54.21 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales LivaNova generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue LivaNova retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare LivaNova's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares LivaNova has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against LivaNova's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
LivaNova stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
LivaNova Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
LivaNova business model & stock analysis
LivaNova SWOT Analysis
Strengths
LivaNova PLC has several strengths that contribute to its competitive advantage in the industry. Firstly, the company has a strong portfolio of innovative medical technology products, allowing it to meet the diverse needs of patients and healthcare professionals. This enables LivaNova to stay ahead of its competitors and maintain a strong market position. Secondly, the company has a global presence, with operations in various countries, which provides it with access to a wide customer base and opportunities for growth. Additionally, LivaNova has a talented and experienced workforce, enabling it to develop and deliver high-quality products and services.
Weaknesses
Despite its strengths, LivaNova PLC also faces certain weaknesses that need to be addressed. One major weakness is the company's heavy dependence on a few key products for a significant portion of its revenue. This exposes LivaNova to risks such as market fluctuations and potential product obsolescence. Another weakness is the company's limited presence in emerging markets, which hinders its ability to tap into the growing demand for medical technology in these regions. Moreover, LivaNova has faced challenges in effectively integrating acquired businesses, resulting in potential operational inefficiencies.
Opportunities
LivaNova PLC has several opportunities that can be capitalized on to drive growth and profitability. The increasing prevalence of chronic diseases and the aging population present a significant opportunity for the company to expand its product offerings and enter new markets. Additionally, the growing demand for minimally invasive surgeries and advanced medical treatments provides LivaNova with the chance to develop innovative solutions that cater to these trends. Furthermore, partnerships and collaborations with healthcare organizations and research institutions can enhance LivaNova's research and development capabilities, leading to new breakthrough products.
Threats
LivaNova PLC operates in an industry that is characterized by intense competition and regulatory challenges, posing threats to its business. The presence of strong competitors with established market positions and significant resources can make it difficult for LivaNova to gain market share. Moreover, the company is subject to strict regulations and compliance requirements, which can impact its ability to introduce new products and expand into certain markets. Additionally, economic downturns and fluctuations in healthcare spending can affect the demand for LivaNova's products and services, presenting a potential threat to its financial performance.
LivaNova Segments
LivaNova Revenue by Segment
3 Years
5 Years
Max
Details
LivaNova Revenue by Region
3 Years
5 Years
Max
Details
LivaNova Eulerpool Fair Value
LivaNova historical P/E ratio, EBIT multiple, and P/S ratio
LivaNova annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
LivaNova shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
LivaNova Earnings Estimates
LivaNova Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/6/2026 | 0.91USD | 353.03 MUSD | 2026 Q1 |
| 2/25/2026 | 0.83USD | 360.38 MUSD | 2025 Q4 |
| 5/1/2024 | 0.56USD | 280.22 MUSD | 2024 Q1 |
| 2/20/2024 | 0.8USD | 293.77 MUSD | 2023 Q4 |
| 11/2/2022 | 0.56USD | 250.69 MUSD | 2022 Q3 |
| 8/3/2022 | 0.53USD | 253.29 MUSD | 2022 Q2 |
| 5/4/2022 | 0.49USD | 235.05 MUSD | 2022 Q1 |
| 2/23/2022 | 0.53USD | 271.21 MUSD | 2021 Q4 |
| 11/3/2021 | 0.45USD | 248.95 MUSD | 2021 Q3 |
| 7/28/2021 | 0.33USD | 247.77 MUSD | 2021 Q2 |
EESG©
Eulerpool ESG Scorecard© for the LivaNova stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
LivaNova shareholder structure
| % | Name |
|---|---|
11.68042% | |
8.50469% | |
4.47072% | |
4.44494% | |
3.8142% | |
3.75604% | |
2.95797% | |
2.61982% | |
2.34208% | |
2.28609% |
LivaNova Executives and Management Board
Mr. Vladimir Makatsaria
(52)Chief Executive Officer, Director · since 2024
Mr. Alex Shvartsburg
(55)Chief Financial Officer
Dr. Ahmet Tezel
(50)Senior Vice President, Chief Innovation Officer
Mr. Michael Hutchinson
(54)Senior Vice President, Chief Legal Officer, Company Secretary
Mr. Franco Poletti
(63)President, Cardiopulmonary Business Unit
LivaNova Supply Chain
Frequently asked questions about LivaNova
Some of the main competitors of LivaNova PLC in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.
LivaNova stock
LivaNova Peer Group
LivaNova Ticker
LivaNova FIGI
All fundamentals and in-depth analysis of LivaNova
Our stock analysis for LivaNova Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of LivaNova Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.